ASD Clinical Trial
Official title:
Assessing the Feasibility, Acceptability, and Preliminary Efficacy of an Adaptive Intervention Approach for Children With Autism and Disruptive Behavior: A Pilot Study
Verified date | March 2022 |
Source | Children's Hospital of Philadelphia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Investigators seek to transform the delivery of health care to children with autism spectrum disorder (ASD) and behavioral health problems (and their families) by developing an innovative tiered set of interventions. Investigators aim to demonstrate that for children with ASD and disruptive behavior a family navigation-based intervention (autism behavioral health navigation; ABHN) will be feasible and more acceptable to families than brief social work consultation. For children with persistent disruptive behavior despite the social work or ABHN intervention Investigators will evaluate the feasibility and acceptability of adding consultation with an interprofessional team of ASD experts.
Status | Completed |
Enrollment | 42 |
Est. completion date | August 27, 2021 |
Est. primary completion date | August 27, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 5 Years to 12 Years |
Eligibility | Inclusion Criteria: 1. Child is age 5 through 12 years 11 months 2. Diagnosed with autism spectrum disorder (ASD) and receives care for ASD at the Children's Hospital of Philadelphia (CHOP) in Developmental and Behavioral Pediatrics (DBP) or Child Neurology, or in Department of Child and Adolescent Psychiatry and Behavioral Sciences (DCAPBS) 3. Child exhibits disruptive behaviors characterized by tantrums, outbursts, self-injurious, or aggressive behaviors with a Clinical Global Impression severity (CGI-S) for the disruptive behavior of at least 4 4. A caregiver completed Aberrant Behavior Checklist (ABC-2) Irritability subscale score is greater than 13 5. A parent of the child who is involved in coordinating the child's care will also participate as a research subject. Exclusion Criteria: 1. Child requires crisis intervention or urgent psychiatric consultation 2. Referring physician or psychologist will not be providing ongoing management of the child's behavioral challenges. 3. Parent needs a different intervention or type of assistance than will be available through the study 4. Families who live outside a 40 mile radius from the Children's Hospital of Philadelphia (CHOP -main) |
Country | Name | City | State |
---|---|---|---|
United States | The Children's Hospital of Philadelphia | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Children's Hospital of Philadelphia | Eagles Autism Challenge, Inc, University of Pennsylvania |
United States,
Adams JS, Woods ER. Redesign of chronic illness care in children and adolescents: evidence for the chronic care model. Curr Opin Pediatr. 2016 Aug;28(4):428-33. doi: 10.1097/MOP.0000000000000368. Review. — View Citation
Bearss K, Johnson C, Smith T, Lecavalier L, Swiezy N, Aman M, McAdam DB, Butter E, Stillitano C, Minshawi N, Sukhodolsky DG, Mruzek DW, Turner K, Neal T, Hallett V, Mulick JA, Green B, Handen B, Deng Y, Dziura J, Scahill L. Effect of parent training vs parent education on behavioral problems in children with autism spectrum disorder: a randomized clinical trial. JAMA. 2015 Apr 21;313(15):1524-33. doi: 10.1001/jama.2015.3150. Erratum in: JAMA. 2016 Jul 19;316(3):350. JAMA. 2016 Jul 19;316(3):350. — View Citation
Chakraborty B, Murphy SA. Dynamic Treatment Regimes. Annu Rev Stat Appl. 2014;1:447-464. — View Citation
Guinchat V, Cravero C, Diaz L, Périsse D, Xavier J, Amiet C, Gourfinkel-An I, Bodeau N, Wachtel L, Cohen D, Consoli A. Acute behavioral crises in psychiatric inpatients with autism spectrum disorder (ASD): recognition of concomitant medical or non-ASD psychiatric conditions predicts enhanced improvement. Res Dev Disabil. 2015 Mar;38:242-55. doi: 10.1016/j.ridd.2014.12.020. Epub 2015 Jan 7. — View Citation
Johnson CR, DeMand A, Lecavalier L, Smith T, Aman M, Foldes E, Scahill L. Psychometric properties of the children's sleep habits questionnaire in children with autism spectrum disorder. Sleep Med. 2016 Apr;20:5-11. doi: 10.1016/j.sleep.2015.12.005. Epub 2015 Dec 29. — View Citation
Laurent PA. The emergence of saliency and novelty responses from Reinforcement Learning principles. Neural Netw. 2008 Dec;21(10):1493-9. doi: 10.1016/j.neunet.2008.09.004. Epub 2008 Sep 25. — View Citation
Linn KA, Laber EB, Stefanski LA. iqLearn: Interactive Q-Learning in R. J Stat Softw. 2015 Feb;64(1). pii: i01. Epub 2015 Mar 20. — View Citation
Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004 Nov;114(5):e634-41. Epub 2004 Oct 18. — View Citation
Volker MA, Lopata C, Smerbeck AM, Knoll VA, Thomeer ML, Toomey JA, Rodgers JD. BASC-2 PRS profiles for students with high-functioning autism spectrum disorders. J Autism Dev Disord. 2010 Feb;40(2):188-99. doi: 10.1007/s10803-009-0849-6. Epub 2009 Aug 25. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of children referred to the study each month meeting eligibility requirements | Prescribing clinicians from the following Divisions and Departments (DBP, Neurology, DCAPBS) will refer patients age 5-12 with ASD and disruptive behavior to the study. The number of children referred will be determined by counting the participants in the study who meet the inclusion criteria. | 9 months | |
Secondary | Number of families successfully contacted by the navigator or social worker | The number of families successfully contacted will be determined by reviewing contact logs of all contacts with the family and who initiated the contact; the duration of all contacts; the location of the contact; and the topic discussed, support provided, or toolkits reviewed. | 9 months | |
Secondary | Retention Rate | The number of families retained will be determined by the number of families who complete treatment Phase 2 | 9 months | |
Secondary | Number of subjects consented | The number of families consented will be measured by the percentage of eligible families consenting to the study | 9 months | |
Secondary | Changes (or Improvement) with interpersonal relationships | This is a nine-item measure designed to assess satisfaction with the interpersonal relationship with the navigator or SW. The measure has been shown to have high internal consistency and to be significantly correlated with overall satisfaction with care and not to be correlated with health literacy or patients' primary language | 9 months | |
Secondary | Changes in ABC-irritability subscale | To meet eligibility the caregiver completed Aberrant Behavior Checklist-2 (ABC-2) Irritability subscale score needs to be > 13 (above the 50th percentile for children with ASD).This change will be measured by comparing the first stage interventions (SW vs. ABHN) and the change in ABC-irritability subscale score between baseline and the intermediate visit at month 3. At month 3, patients whose ABC Irritability subscale scores demonstrate improvement of at least 5 points (approximately ½ SD; moderate effect size) will remain in the same intervention. Patients whose ABC Irritability subscale scores suggest minimal to no improvement (less than 5 point improvement) will be randomized to either ABHN or ABHN+CAP if they were in the social work group in Phase 1 or will receive ABHN+CAP if they were in the ABHN arm of the study in phase 1. The primary efficacy endpoint for comparing the three embedded regimes will be ABC-irritability subscale at month 6. | 6 months | |
Secondary | Changes in levels of challenging behavior | This will be measured by the Clinician Global Impression Scales (CGI). The CGI consists of a severity scale (CGI-S) and an Improvement scale (CGI-I). For the CGI-I, clinicians use record review to rate the level of change from the screening/baseline visit (1-3 indicating improvement, 4 indicating no change, 5-7 indicating a worsening of symptoms). The CGI-I will be completed at the 3- and 6-month follow up visits, and will measure the level of improvement compared to the CGI-S taken at screening/baseline. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02847182 -
Cord Blood Infusion for Children With Autism Spectrum Disorder
|
Phase 2 | |
Completed |
NCT02708290 -
Mental Imagery Therapy for Autism (MITA) - an Early Intervention Computerized Language Training Program for Children With ASD
|
||
Completed |
NCT04771338 -
Examining the Effects of a Job Entry Intervention
|
N/A | |
Completed |
NCT04178421 -
Computerized Eye-tracking Attention Training for Children With Special Needs
|
N/A | |
Completed |
NCT02985749 -
A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
|
Phase 3 | |
Recruiting |
NCT06012903 -
Lower Urinary Tract Symptoms and School Functioning in Children
|
||
Not yet recruiting |
NCT04418921 -
Improving Self-regulation in Children With Neurodevelopmental Disorders:
|
N/A | |
Completed |
NCT01931033 -
An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders
|
N/A | |
Recruiting |
NCT04899544 -
Trial of Center-Based vs. In-Home Pivotal Response Treatment (PRT) in Autism
|
N/A | |
Recruiting |
NCT06155214 -
Developmental Regression-related Disease Research and Achievement Transformation Innovation Team
|
||
Active, not recruiting |
NCT01932515 -
Diagnostic Instruments for Autism in Deaf Children Study
|
N/A | |
Recruiting |
NCT06188429 -
Peripheral Blood VA/TREM2 Levels and Their Correlation Analysis With the Development and Autistic Symptoms in Children With ASD
|
||
Completed |
NCT06209463 -
Posture, Hand Functions and Sensory Processing Skills on Nutrition
|
||
Recruiting |
NCT06155201 -
Development and Application of Intelligent Diagnosis and Treatment Norms for Children and Adolescents With Mental Disorders
|
N/A | |
Recruiting |
NCT03502239 -
Cognitive Rehabilitation (Mega Team) and Its Effects on Emotional and Behavioral Regulation in ADHD, ASD, and CHD
|
N/A | |
Withdrawn |
NCT03829878 -
Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT)
|
Phase 2 | |
Recruiting |
NCT02461446 -
Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations
|
||
Completed |
NCT03900923 -
Cannabidiol for ASD Open Trial
|
Phase 2 | |
Recruiting |
NCT06339359 -
A Pilot Study to Develop a Behavior-based Screening Protocol for Early Diagnosis of Autism Spectrum Disorders
|
||
Completed |
NCT03099239 -
hCT-MSCs for Children With Autism Spectrum Disorder (ASD)
|
Phase 1 |